Genmab A/S (NASDAQ:GMAB) Price Target Lowered to $50.00 at Truist Financial

Genmab A/S (NASDAQ:GMAB) had its price objective reduced by equities research analysts at Truist Financial from $53.00 to $50.00 in a research note issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 81.82% from the stock’s previous close.

A number of other research analysts also recently weighed in on the company. BTIG Research lifted their price target on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Tuesday, August 27th. Finally, Morgan Stanley restated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $45.20.

Genmab A/S Trading Up 0.1 %

Shares of GMAB opened at $27.50 on Monday. The business’s 50-day moving average price is $27.16 and its 200 day moving average price is $28.10. The stock has a market capitalization of $18.19 billion, a P/E ratio of 22.92, a P/E/G ratio of 0.87 and a beta of 0.99. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $38.80.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, research analysts predict that Genmab A/S will post 1.21 earnings per share for the current year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC acquired a new stake in Genmab A/S in the 4th quarter worth approximately $393,000. M&T Bank Corp grew its stake in Genmab A/S by 87.8% in the 4th quarter. M&T Bank Corp now owns 15,432 shares of the company’s stock valued at $492,000 after buying an additional 7,213 shares during the last quarter. Principal Securities Inc. acquired a new position in Genmab A/S during the 4th quarter worth $77,000. Envestnet Portfolio Solutions Inc. boosted its holdings in Genmab A/S by 32.7% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 27,122 shares of the company’s stock valued at $864,000 after acquiring an additional 6,681 shares during the period. Finally, Torray Investment Partners LLC grew its position in shares of Genmab A/S by 2.6% in the fourth quarter. Torray Investment Partners LLC now owns 107,201 shares of the company’s stock valued at $3,413,000 after purchasing an additional 2,685 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.